Clinical Characteristics of Two Human to Human Transmitted Coronaviruses: Corona Virus Disease 2019 versus Middle East Respiratory Syndrome Coronavirus.

Ping Xu, MD, Ph.D, Guo-Dong Sun, MD, Ph.D, Zhi-Zhong Li*, MD, Ph.D.

Investigation performed at the Department of Spinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.

Ping Xu MD, Ph.D, Department of Spinal Surgery, The First Affiliated Hospital of Jinan University, 601 West Whampoa Avenue, Guangzhou 510000, China; E-mail: xphandsome@163.com

Guo-Dong Sun Ph.D, Department of Spinal Surgery, The First Affiliated Hospital of Jinan University, 601 West Whampoa Avenue, Guangzhou 510000, China; E-mail: sgd96@jnu.edu.cn

Zhi-Zhong Li MD, Ph.D, Department of Spinal Surgery, The First Affiliated Hospital of Jinan University, 601 West Whampoa Avenue, Guangzhou 510000, China; E-mail: lizhizhonghy@163.com

Address correspondence and reprint requests to Zhi-Zhong Li MD, Ph.D. Department of Spinal Surgery, The First Affiliated Hospital of Jinan University, 601 West Whampoa Avenue, Guangzhou 510000, China; Telephone:13392692223, E-mail: lizhizhonghy@163.com

Conflict of Interest Statement: Each author certifies that he or immediate family has no funding or commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangements, etc).

Abstract

After the outbreak of the middle east respiratory syndrome (MERS) worldwide in 2012.

Currently, a novel human coronavirus has caused a major disease outbreak, and named corona

virus disease 2019 (COVID-19). The emergency of MRES-COV and COVID-19 has caused

global panic and threatened health security. Unfortunately, the similarities and differences

between the two coronavirus diseases remain to be unknown. The aim of this study, therefore,

is to perform a systematic review to compare epidemiological, clinical and laboratory features

of COVID-19 and MERS-COV population. We searched PubMed, EMBASE and Cochrane

Register of Controlled Trials database to identify potential studies reported COVID-19 or

MERS-COV. Epidemiological, clinical and laboratory outcomes, the admission rate of

intensive cure unit (ICU), discharge rate and fatality rate were evaluated using GraphPad

Prism software. Thirty-two studies involving 3770 patients (COVID-19 = 1062, MERS-COV

= 2708) were included in this study. The present study revealed that compared with COVID-

19 population, MERS-COV population had a higher rate of ICU admission, discharge and

fatality and longer incubation time. It pointed out that fever, cough and generalised weakness

and myalgia were main clinical manifestations of both COVID-19 and MERS-COV, whereas

ARDS was main complication. The most effective drug for MERS-COV is ribavirin and

interferon.

Keywords: COVID-19, MERS-COV, Clinical chaeacteristics, complication, ICU admission

2

rate, Fatality rate.

Introduction

Coronaviruses are RNA viruses with envelope and non-segmented positive-sense, causing respiratory and intestinal tract infections in humans and other mammals [1]. Despite majority of patients present mild symptoms and good prognosis, the spread of two β-coronaviruses, severe acute respiratory syndrome coronavirus (SARS-COV) and middle east respiratory syndrome coronavirus (MERS-COV), have resulted in the infection of thousands of individuals in past decades, with the fatality rate of 10% for SARS-COV population and 37% for MERS-COV population [2-4]. Before 2019, there is a total of six identified coronaviruses, but that might only be a small part of the iceberg, with potentially more novel and terrible zoonoses to be presented.

As December 8, 2019, a series of unexplained pneumonia cases linked to Huanan seafood wholesale market has been reported in Wuhan, Hubei, China [5-6]. Clinical characteristics of this pneumonia were very similar to those of viral pneumonia such as MERS-COV, initially severe acute respiratory infection, followed by developing rapidly acute respiratory distress syndrome (ARDS) and even acute respiratory failure [7]. Sequencing data from throat swab samples of a patient indicated a novel coronavirus subsequently named corona virus disease 2019 (COVID-19) by world health organization (WHO). So far, more than 70000 confirmed cumulative cases have been reported in China, and more than 10000 confirmed cumulative cases in other countries such as South Korea, Japan, Italy, Iran and the USA.

Although many previous studies have reported clinical characteristics of COVID-19 or

MERS-COV diseases [8-11], systematic comparison of clinical features between COVID-19

and MERS-COV diseases has yet been published. Thus, the purpose of this study is to

perform a systematic review of epidemiological, clinical and laboratory characteristics of

patients infected by COVID-19 or MERS-COV disease, and to compare COVID-19 and

MERS-COV in the context of their incubation, laboratory features, admission rate of intensive

cure unit (ICU) and rate of discharge and fatality, which will provide a comprehensive

reference for clinical physicians in treatment of coronavirus diseases.

Material and Methods

Search strategy

A comprehensive and systematic search was performed using PubMed, EMBASE and

Cochrane Register of Controlled Trials database up to 26 February 2020. Medical Subject

Heading (MSH) terms and keywords were used so as to retrieve as many potential documents

as possible. Terms for MERS-COV included: Middle East Respiratory Syndrome Coronavirus

[Mesh] OR MERS-CoV OR MERS Virus OR MERS Viruses OR Virus, MERS OR Viruses,

MERS OR Middle East respiratory syndrome-related coronavirus OR Middle East respiratory

syndrome related coronavirus. They were combined with terms specifying COVID-19:

((Wuhan coronavirus) OR (Wuhan seafood market pneumonia virus) OR (SARS2) OR

(COVID-19 virus) OR (coronavirus disease 2019 virus) OR (SARS-CoV-2) OR (2019-nCoV)

OR (2019 novel coronavirus)). If necessary, we also contacted corresponding author to obtain

4

accurate data.

Eligibility criteria

The study that met following criteria were included: (1) reporting clinical characteristics of COVID-19 or MERS-COV disease, (2) minimum sample size of five, (3) confirmed COVID-19 or MERS-COV disease, (4) English literature. Studies were excluded as following criteria: duplicate publications, case report, meta-analysis, letter, review, technology report, commentary, animal trial, correspondence, predictive study, guidence, radiograph study and meeting report.

Study Selection

At the beginning, 4743 potential publications were identified. We removed 678 duplicates and reviewed the titles and abstracts of remaining 4065 publications. 4015 publications were excluded for following reasons: not involved research point (n = 1378), review (n = 569), no English (n = 33), case report (n = 316), meta-analysis (n = 1), letter (n = 127), technology report (n = 196), commentaries (n = 61), animal study (n = 1107), correspondence (n = 29), predictive study (n = 110), guidence (n = 28), meeting report (n = 16) and radiograph (n = 44). Then, a comprehensive review of full-text was conducted for remaining 50 publications. Two reviewers independently screened eligible literature, and any argument was solved by discussion with a third reviewer. Finally, thirty-two studies were included in this study [8-39]. The process was shown in Figure 1.

Data Extraction

Two reviewers extracted independently common, clinical and laboratory characteristics of included studies, with disagreements were solved by discussion with a third reviewer. The extracted data included incubation time, white blood cell (WBC) count, lymphocyte count, c-reactive protein (CRP), alamine aminotransferase (ALT), aspartate aminotransferase (AST),

creatinine, creatine kinase (CK), the admission rate of intensive cure unit (ICU), rate of

discharge and fatality, symptom, comorbidity, complications and cure rate of drug. For

normality distribution data, outcomes were extracted directly. For skewness distribution data,

the outcomes was extracted after being converted as specific formula [40].

Quality Assessment

The quality assessment of included studies was performed through the Newcastle-Ottawa

Quality Assessment Scale (NOS), as recommended by the Cochrane Non-Randomized

Studies [41]. The NOS includes three parts for risk of bias, with nine points in total: (1)

selection of research groups (four points); (2) inter-group comparability (two points); and (3)

ascertainment of exposure and outcomes (three points) for case-control and cohort studies,

respectively. Study that scored 6 or more was qualified for systematic review [42]. The

assessment process was completed by two reviewers independently. All debates were solved

by discussion with a third reviewer.

Statistical Analysis

All statistical analyses and graphs were generated and plotted using GraphPad Prism

version 7.00 software (GraphPad Software Inc). The p value < 0.05 suggests significant

difference.

Results

Study Characteristics

All included studies were retrospective study [8-39]. Among ten studies reported

COVID-19, one trial was performed in Netherlands [12] and remaining nine trials were

conducted in China [8-9, 13-16, 37-39]. The sample size ranged from 6 to 425, and had a total

of 1062 patients (male = 610, female = 452). The year of publications was in 2020. On the other hand, among twenty-two studies reported MERS-COV, fifteen studies were conducted in Saudi Arabia [11, 17-18, 20-23, 27-30, 32, 34-36], five trials were performed in South Korea [24-26, 31, 33], one trial was performed in Iran [19] and one trial was conducted in Japan [10]. The sample size ranged from 5 to 883, and had a total of 2708 patients. The year of publications ranged from 2013 to 2020. Clinical and laboratory characteristics of included study were shown in Table 1 and Table 2 respectively.

Quality Assessment

Among thirty-two included studies, four studies obtained 6 points of NOS [26, 28, 32, 35], and remaining twenty-eight studies obtained 7 points of NOS or more [8-25, 27, 29-31, 33-34, 36-39]. The result of quality assessment was presented in Table 3.

Clinical Symptom

For COVID-19 population, the number of patients with fever was 480 (45.2%), cough was 373 (35.1%), generalised weakness and myalgia was 318 (29.9%), stuffy or rhinorrhoea was 6 (0.6%), pharyngalgia was 32 (3%), chest pain was 10 (0.9%), diarrhoea or anorexia was 123 (11.6%), dyspnoea was 140 (13.2%) and dizziness or headache was 60 (5.6%). For MERS-COV population, the amount of patients with fever was 404 (14.9%), cough was 424 (15.7%), generalised weakness and myalgia was 337 (12.4%), stuffy or rhinorrhoea was 17 (0.6%), pharyngalgia was 47 (1.7%), chest pain was 27 (1%), diarrhoea or anorexia was 128 (4.7%), dyspnoea was 271 (10%) and dizziness or headache was 131 (4.8%). The Above results were shown in Table 4.

Complications

For COVID-19 population, the main complications included shock, arrhythmia, acute respiratory distress syndrome (ARDS), acute cardiac injury, acute kidney injury and acute

liver injury, and the amount of which was 17 (1.6%), 28 (2.6%), 51 (4.8%), 11 (1%), 10 (0.9%) and 2 (0.2%) respectively. For MERS-COV population, the number of individuals presented shock was 22 (0.8%), arrhythmia was 11 (0.4%), ARDS was 83 (3.1%), acute cardiac injury 10 (0.4%), acute kidney injury was 30 (1.1%), acute liver injury was 22 (0.8%) and neurological symptoms was 4 (0.1%). The results were shown in Table 5.

Comorbidity

Among COVID-19 population, 43 (4%) patients had diabetes, 101 (9.5%) patients had hypertension, 77 (7.3%) patients had cardiovascular disease, 10 (0.9%) patients had chronic obstructive pulmonary disease (COPD), 19 (1.8%) patients had malignancy, 24 (2.3%) patients had chronic liver disease, 13 (1.2%) patients had cerebrovascular disease and 5 (0.5%) patients had chronic kidney disease. Among MERS-COV population, the number of patients with diabetes was 247 (9.1%), hypertension was 244 (9%), cardiovascular disease was 161 (5.9%), COPD was 83 (3.1%), malignancy was 70 (2.6%), chronic liver disease was 28 (1%), cerebrovascular disease was 47 (1.7%), chronic kidney disease was 167 (6.2%) and obesity was 42 (1.6%). Those results were shown in Table 6.

Clinical and Laboratory Characteristics of COVID-19 versus MERS-COV

Systematic review was performed for clinical and laboratory outcomes of coronavirus disease. There was no significant difference in age $(50.9 \pm 2 \text{ vs. } 53.6 \pm 1.5, \text{ P} = 0.3)$, WBC $(5.7 \pm 0.4 \text{ vs. } 7.6 \pm 1, \text{ P} = 0.1)$, lymphocyte count $(1.1 \pm 0.1 \text{ vs. } 0.8 \pm 0.1, \text{ P} = 0.2)$, CRP $(37.6 \pm 5.8 \text{ vs. } 13.9 \pm 11.3, \text{ P} = 0.1)$, ALT $(28 \pm 3.1 \text{ vs. } 37.3 \pm 5.1, \text{ P} = 0.2)$, creatinine $(74.5 \pm 0.4 \text{ vs. } 101.4 \pm 18.5, \text{ P} = 0.2)$ and creatine kinase $(109.1 \pm 20 \text{ vs. } 136.4 \pm 23.1, \text{ P} = 0.5)$ between COVID-19 and MERS-COV population. Compared with COVID-19 population, a higher AST $(31.5 \pm 2.4 \text{ vs. } 58.3 \pm 7.6, \text{ P} = 0.009)$ and longer incubtion time $(5.1 \pm 0.5 \text{ vs. } 7.4 \pm 0.4, \text{ P} = 0.02)$ were found in MERS-COV population. The results were shown in Table 7.

Incidence of ICU Admission, Discharge and Fatality

The higher admission rate of ICU was found in MERS-COV population than in COVID-19 population (43.6% vs. 22.4%, Figure 2). There was a higher discharge rate in MERS-COV populations compared with COVID-19 population (59.9% vs. 33.5%, Figure 3). The lower fatality rate was found in COVID-19 population compared with MERS-COV population (6.8% vs. 34.1%, Figure 4).

Cure rate of drugs for MERS-COV

Of 93 patients treated by ribavirin and interferon, 67 (74.2%) were cured. Of 39 patients treated by oseltamivir, 27 (69.2%) were cured. Of 70 patients treated by antivirals, 47 (67.1%) were cured. Of 8 patients treated by intravenous immunoglobulin, 5 (62.5%) were cured. Of 9 patients treated by ribavirin and lopinavir/ritonavir, 4 (44.4%) were cured. Of 18 patients treated by corticosteroids, 7 (38.9%) were cured. The results were shown in Figure 5.

Discussion

Coronavirus is an important pathogen causing respiratory and intestinal infection. Of seven identified coronaviruses, the two very pathogenic viruses, SARS-COV and MERS-COV, cause severe ARDS and even acute respiratory failure. With a mortality rate of more than 10% and more than 35% respectively [43-44]. The four other human coronaviruses (HCoV-OC43, HCoV-229E, HCoV-NL63, HCoV-HKU1) only cause mild respiratory or intestinal infection, despite they have certain pathogenicity for infants, young children and the elderly with weakened immune systems [45-46]. The newest one is COVID-19. The sequencing analysis has indicated that COVID-19, like SARS-COV and MERS-COV, belongs to β-coronavirus. Both SARS-COV and MERS-COV originated in bats, but the origin of COVID-19 remains to be further investigated. Although recent studies have reported the clinical and laboratory features of COVID-19, systematic comparsion between COVID-19

and MERS-COV has yet been performed. Therefore, the aim of this study is to perform the first systematic review to compare epidemiological, clinical and laboratory characteristics of COVID-19 and MERS-COV populations. Our results suggested that fever, cough and generalised weakness and myalgia were main clinical manifestations of both COVID-19 and MERS-COV, whereas ARDS was main complication. Compared with MERS-COV population, COVID-19 population had a less incubation time and lower rate of ICU admission, discharge and fatality.

Similarities of clinical characteristics between COVID-19 and MERS-COV have been found. In the current study, the majority of COVID-19 patients presented with fever, cough and generalised weakness and myalgia, which shows some resemblances to MERS-COV infection. Moreover, both COVID-19 and MERS-COV patients hardly developed upper respiratory tract infection such as rhinorrhoea or pharyngalgia, indicating that their target cells might be located in lower respiratory. However, 11.6% of patients with COVID-19 infection had diarrhoea or anorexia, and only 4.7% of patients with MERS-COV infection had this symptom. Thus, Faces and urine samples should be tested to exclude a potential alternative way of transmission that is unknown to the present.

In addition, we found that the number of males is more than that of females in either COVID-19 or MERS-COV population. The possible reason of reduced susceptibility of females to viral infection is that females have a lot of X chromosome and estrogen that are vital components in development of innate and adaptive immunity [47]. Meanwhile, numbers of patients with COVID-19 infection had chronic comorbidities, mainly hypertension, diabetes and cardiovascular disease, which is similar to MERS-COV population. Those results indicate that older adult males with chronic underlying disease might be more susceptibility to COVID-19 or MERS-COV.

In terms of laboratory testing, reduced lymphocytes and increased CRP were found in both COVID-19 and MERS-COV patients. This result indicates that COVID-19 might be associated with cellular immune response, mainly act on lymphocytes like MERS-COV does [48]. The cells infected by viruses induce the release of numbers of pro-inflammatory cytokines and inflammation storm in the body. Moreover, increased cytokines might make damage to related organs such as liver [49]. Our results demonstrated that abnormal value of AST was found in MERS-COV population, but not in COVID-19 population. The possible reason is that the follow-up time of COVID-19 population was too short, and the liver might remain to be in compensatory stage. For this result, a long follow-up time study is urgently needed. On the other hand, our results suggested that MERS-COV population had a higher rate of ICU admission and fatality than COVID-19 population, indicating that compared with MERS-COV, COVID-19 has less toxic and more easily cured. However, lower discharge rate was found in COVID population than in MERS-COV population. The possible explanation is that most of COVID-19 patients remained to be hospitalized at the time of manuscript submission, and data on those patients could not be obtained in time. Thus, careful interpretation is urged for this result.

Up to now, no effective strategy has been found for treatment of COVID-19 infection [50]. Currently, the measure to COVID-19 is to control the source of the infection; taking personal protective works to reduce the risk of transmission; and early diagnosing, isolating and supportive treating for confirmed patients. In the present study, our systematic results of cure rate of drug for MERS-COV infection indicated that ribavirin and interferon, oseltamivir, antivirals and intravenous immunoglobulin all had been effective for MERS-COV infection, with the cure rate of those drugs was 74.2%, 69.2%, 67.1% and 62.5% respectively. Thus, we

assume that those drugs might also be effective at COVID-19 infection. However, further

studies are needed to confirm this idea.

This study has several limitations. First, many patients infected by COVID-19 remained

to be hospitalized at the time of manuscript submission, leading to the unavailable of some

data. Second, the follow-up time of COVID-19 population is too short to get related data from

long-term observations of this disease. Third, finding of statistical tests and p values between

COVID-19 and MERS-COV populations should be interpreted with caution. Fourth, the

number of MERS-COV patients treated by drugs is small, careful understanding is needed for

the cure rate of drug for this disease. Finally, as COVID-19 is still developing around the

world and remains to have many unknowns, the results of this study are staged and need to be

carefully understood. More large-sample, multicentre, high-quality research should be

performed to update this study.

Conclusion

Our systematic review reveals that main clinical manifestations of both COVID-19 and

MERS-COV populations are fever, cough and generalised weakness and myalgia. ARDS is

main complication of both two populations. COVID-19 population has a shorter incubation

time and lower rate of ICU admission, discharge and fatality compared with MRES-COV

population.

Acknowledgments:

This study was supported by grants from the National Natural Science Foundation of

China (Nos.31970862) and Guangzhou Municipal Science and Technology project (Nos.

12

201803010001, Prof. Zhi-Zhong Li)

Reference

- [1] Richman DD, Whitley RJ, Hayden FG. Clinical virology. 4th ed. Washington: ASM Press; 2016.
- [2] Yin Y, Wunderink RG MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23:130–37.
- [3] Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–76.
- [4] Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–20.
- [5] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020;92:401-402.
- [6] Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–66.
- [7] WHO. Novel coronavirus China. 12 Jan 2020. Available from http://www.who. int/csr/don/12-january-2020-novel-coronavirus-china/en/
- [8] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
- [9] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. DIO:10.1001/jama.2020.1585.
- [10] Hwang SM, Na BJ, Jung Y, et al. Clinical and Laboratory Findings of Middle East Respiratory Syndrome Coronavirus Infection. Jpn J Infect Dis. 2019;72(3):160–167.

- [11] Al-Baadani AM, Elzein FE, Alhemyadi SA, et al. Characteristics and outcome of viral pneumonia caused by influenza and Middle East respiratory syndrome-coronavirus infections: A 4-year experience from a tertiary care center. Ann Thorac Med. 2019;14(3):179–185.
- [12] Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020;25(5).
- [13] Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523.
- [14] Song F, Shi N, Shan F, et al. Emerging Coronavirus 2019-nCoV Pneumonia. Radiology. 2020. DIO:10.1148/radiol.2020200274.
- [15] Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–374.
- [16] Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020. DIO: 10.1056/NEJMoa2001316.
- [17] Alfaraj SH, Al-Tawfiq JA, Assiri AY, et al. Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: A cohort study. Travel Med Infect Dis. 2019;29:48–50.
- [18] Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and Interferon Therapy for Critically III Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. Clin Infect Dis. 2019. DIO:10.1093/cid/ciz544.

- [19] Ahmadzadeh J, Mobaraki K. Epidemiological status of the Middle East respiratory syndrome coronavirus in 2019: an update from January 1 to March 31, 2019. Int J Gen Med. 2019;12:305–311.
- [20] Habib AMG, Ali MAE, Zouaoui BR, et al. Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. BMC Infect Dis. 2019;19(1):870.
- [21] Ahmed AE. Estimating survival rates in MERS-CoV patients 14 and 45 days after experiencing symptoms and determining the differences in survival rates by demographic data, disease characteristics and regions: a worldwide study. Epidemiol Infect. 2018;146(4):489–495.
- [22] Garout MA, Jokhdar HAA, Aljahdali IA, et al. Mortality rate of ICU patients with the Middle East Respiratory Syndrome Coronavirus infection at King Fahad Hospital, Jeddah, Saudi Arabia. Cent Eur J Public Health. 2018;26(2):87–91.
- [23] Shalhoub S, Al-Hameed F, Mandourah Y, et al. Critically ill healthcare workers with the middle east respiratory syndrome (MERS): A multicenter study. PLoS One. 2018;13(11):e0206831.
- [24] Kim KH, Tandi TE, Choi JW, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. J Hosp Infect. 2017;95(2):207–213.
- [25] Kang CK, Song KH, Choe PG, et al. Clinical and Epidemiologic Characteristics of Spreaders of Middle East Respiratory Syndrome Coronavirus during the 2015 Outbreak in Korea. J Korean Med Sci. 2017;32(5):744–749.
- [26] Kim JE, Heo JH, Kim HO, et al. Neurological Complications during Treatment of Middle East Respiratory Syndrome. J Clin Neurol. 2017;13(3):227–233.

- [27] Garbati MA, Fagbo SF, Fang VJ, et al. A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes. PLoS One. 2016;11(11):e0165978.
- [28] Al-Hameed F, Wahla AS, Siddiqui S, et al. Characteristics and Outcomes of Middle East Respiratory Syndrome Coronavirus Patients Admitted to an Intensive Care Unit in Jeddah, Saudi Arabia. J Intensive Care Med. 2016;31(5):344–348.
- [29] Khalid I, Alraddadi BM, Dairi Y, et al. Acute Management and Long-Term Survival Among Subjects With Severe Middle East Respiratory Syndrome Coronavirus Pneumonia and ARDS. Respir Care. 2016;61(3):340–348.
- [30] Alraddadi B, Bawareth N, Omar H, et al. Patient characteristics infected with Middle East respiratory syndrome coronavirus infection in a tertiary hospital. Ann Thorac Med. 2016;11(2):128–131.
- [31] Choi WS, Kang CI, Kim Y, et al. Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea. Infect Chemother. 2016;48(2):118–126.
- [32] Oboho IK, Tomczyk SM, Al-Asmari AM, et al. 2014 MERS-CoV outbreak in Jeddah--a link to health care facilities. N Engl J Med. 2015;372(9):846–854.
- [33] Cha RH, Joh JS, Jeong I, et al. Renal Complications and Their Prognosis in Korean Patients with Middle East Respiratory Syndrome-Coronavirus from the Central MERS-CoV Designated Hospital. J Korean Med Sci. 2015;30(12):1807–1814.
- [34] Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis. 2014;29:301–306.

- [35] Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42–46.
- [36] Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160(6):389–397.
- [37] Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.
- [38] Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. DIO:10.1111/all.14238.
- [39] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
- [40] Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
- [41] Wells G, Shea B, O'Connell D et al The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- [42] Yuhara H, Steinmaus C, Cohen SE, et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011; 106(11):1911-21.
- [43] Yin Y, Wunderink RG MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23:130–37.

- [44] Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11:59.
- [45] Cui, J.; Li, F.; Shi, Z.L. Origin and evolution of pathogenic coronaviruses. Nat Rev. Microbiol. 2019;17:181–192.
- [46] Su, S.; Wong, G; Shi, W.; Liu, J.; Lai, A.C.; Zhou, J.; Liu, W.; Bi, Y.; Gao, G.F. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24:490–502.
- [47] Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allergy Immunol 2019;56: 308–21.
- [48] Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis 2016;49: 129–33.
- [49] van den Broek MA, Shiri-Sverdlov R, Schreurs JJ, et al. Liver manipulation during liver surgery in humans is associated with hepatocellular damage and hepatic inflammation. Liver Int. 2013;33(4):633–641.
- [50] de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14 (8):523-534.

Table.1 Common and Clinical Characteristics of Included Studies											
Study ID	Study design	Country	Confirmed Disease	Number of patients	Patients age (y) mean/median ± SD or (range)	Male/Female	Incubation period (d) mean ± SD or (range)	Temperature(°C) mean ± SD or (range)	ICU Rate (%)	Discharge Rate (%)	Fatality Rate (%)
Backer et al 2020	Retrospective	Netherlands	COVID-19	88	(2-72)	57/31	6.4 ±6.7	NA	NA	NA	NA
Chan et al 2020	Retrospective	China	COVID-19	6	46.2 ± 22.5	3/3	4.5 ± 1.3	37.7 ± 1.4	NA	NA	NA
Song et al 2020	Retrospective	China	COVID-19	51	49 ± 16	25/26	NA	NA	NA	NA	NA
Huang et al 2020	Retrospective	China	COVID-19	41	49 ± 12.6	30/11	NA	NA	13/41	35/41	6/41
Wang et al 2020	Retrospective	China	COVID-19	138	56 ± 19.3	75/63	NA	NA	36/138	47/138	6/138
Liu et al 2020	Retrospective	China	COVID-19	12	53.7 ± 18	8/4	5.6 ± 4.2	NA	6/12	NA	NA
Chen et al 2020	Retrospective	China	COVID-19	99	55 ± 13.1	67/32	NA	NA	23/99	31/99	11/99
Xu et al 2020	Retrospective	China	COVID-19	62	41 ± 14.8	36/27	4 ± 1.5	NA	1/62	1/62	0/62
Zhang et al 2020	Retrospective	China	COVID-19	140	57 ± 15.5	71/69	NA	NA	NA	NA	NA
Li et al 2020	Retrospective	China	COVID-19	425	59	238/187	5.2	≥ 38	NA	NA	NA
Alfaraj et al 2020	Retrospective	Saudi Arabia	MERS-COV	314	48 ± 17.3	NA	NA	NA	NA	236/314	78/314
Arabi et al 2019	Retrospective	Saudi Arabia	MERS-COV	144	57.5 ± 17	101/43	NA	NA	NA	37/144	107/144
Ahmadzadehet al 2019	Retrospective	Iran	MERS-COV	107	50 ± 17	80/27	NA	NA	NA	89/107	18/107
Habib et al 2019	Retrospective	Saudi Arabia	MERS-COV	63	59.7 ± 18.2	47/16	NA	NA	NA	NA	16/63
Al-Baadani et al 2018	Retrospective	Saudi Arabia	MERS-COV	82	61.6 ± 21	53/29	NA	NA	23/82	45/82	37/82
Hwang et al 2018	Retrospective	Janpan	MERS-COV	7	43 ± 28.2	5/2	8.1 ± 6.8	≥ 37.8	NA	NA	NA
Ahmed et al 2018	Retrospective	Saudi Arabia	MERS-COV	883	54.3 ± 17.6	610/273	(2-14)	NA	NA	NA	323/883
Garout et al 2018	Retrospective	Saudi Arabia	MERS-COV	52	15-85	40/12	NA	NA	52/52	13/52	39/52
Shalhoub et al 2018	Retrospective	Saudi Arabia	MERS-COV	32	39	16/16	NA	≥38	32/32	24/32	8/32
Kim et al 2017	Retrospective	South Korea	MERS-COV	186	55	111/75	NA	NA	NA	148/186	38/186
Kang et al 2017	Retrospective	South Korea	MERS-COV	171	54.4 ± 16.2	99/72	7.1 ± 4.5	≥ 38.5	36/171	140/171	31/171
Kim et al 2017	Retrospective	South Korea	MERS-COV	23	46 ± 7.5	14/9	7 ± 2.8	NA	6/23	19/23	4/23
Garbati et al 2016	Retrospective	Saudi Arabia	MERS-COV	25	60 ± 16.3	9/16	NA	NA	21/25	9/25	16/25
Khalid et al 2016	Retrospective	Saudi Arabia	MERS-COV	14	54 ± 14	9/5	NA	>38	14/14	5/14	9/14
Alraddadi et al 2016	Retrospective	Saudi Arabia	MERS-COV	39	40 ± 19	21/18	NA	NA	27/39	28/39	11/39
Choi et al 2016	Retrospective	South Korea	MERS-COV	186	55 ± 17.5	110/76	NA	NA	45/186	158/186	28/186
Oboho et al 2015	Retrospective	Saudi Arabia	MERS-COV	255	45 ± 21.5	174/81	NA	NA	93/255	62/255	93/255
Cha et al 2015	Retrospective	South Korea	MERS-COV	30	54 ± 20.7	17/37	NA	NA	15/30	12/30	5/30
Al-Hameed et al 2015	Retrospective	Saudi Arabia	MERS-COV	8	56.5 ± 17	6/2	NA	38.4 ± 0.8	8/8	2/8	6/8
Saad et al 2014	Retrospective	Saudi Arabia	MERS-COV	70	62 ± 22.3	46/24	NA	NA	49/70	19/70	42/70
Arabi et al 2014	Retrospective	Saudi Arabia	MERS-COV	12	59 ± 11.75	8/4	NA	NA	12/12	5/12	7/12
Al-Tawfiq et al 2013	Retrospective	Saudi Arabia	MERS-COV	5	57.6 ± 20.8	3/2	NA	NA	5/5	0/5	5/5
COVID-19: Corona Virus Disease-19, MERS-COV: Middle East Respiratory Syndrome-Coronavirus, SD: Standard Deviation, ICU: Intensive Cure Unit, NA: No Available											

Table.2 Laboratory Outcomes of Included Studies

Kim et al 2017

Garbati et al 2016

Khalid et al 2016

Choi et al 2016

Oboho et al 2015

Al-Hameed et al 2015

Cha et al 2015

Saad et al 2014

Arabi et al 2014

Al-Tawfig et al 2013

NA: No Available

COVID-19: Corona Virus Disease-19,

Alraddadi et al 2016

Retrospective

South Korea

Saudi Arabia

Saudi Arabia

Saudi Arabia

South Korea

Saudi Arabia

South Korea

Saudi Arabia

Saudi Arabia

Saudi Arabia

Saudi Arabia

Table.2 Laboratory O	utcomes of Inciu	ded Studies									
Study ID	Study design	Country	Confirmed Disease	Number of patients	WBC (x 10 ⁹ cells/L) mean ±SD or (range)	Lymphocyte count (x 10 ⁹ cells/L) mean ±SD or (range)		ALT (U/L) mean ±SD or (range)	AST (U/L) mean ± SD or (range)	Creatinine (umol/L) mean ± SD or (range)	Creatine kinase (U/L) mean ± SD or (range)
Backer et al 2020	Retrospective	Netherlands	COVID-19	88	NA	NA	NA	NA	NA	NA	NA
Chan et al 2020	Retrospective	China	COVID-19	6	6.1 ± 2.7	1.7 ± 1	23.4 ± 24.6	19.2 ± 5	24.2 ± 4.2	67.7 ± 18.3	93.2 ± 43.3
Song et al 2020	Retrospective	China	COVID-19	51	NA	NA	NA	NA	NA	NA	NA
Huang et al 2020	Retrospective	China	COVID-19	41	6.2 ± 4.7	0.8 ± 0.4	NA	32 ±21.5	34 ± 32.6	74.2 ± 20.9	132.5 ± 116.3
Wang et al 2020	Retrospective	China	COVID-19	138	4.5 ± 2.1	0.8 ± 0.4	NA	24 ± 17.8	31 ± 20	72 ± 20	92 ± 54.8
Liu et al 2020	Retrospective	China	COVID-19	12	6 ± 2.6	1.4 ± 1	41.1 ± 27.5	31.6 ± 12.3	40 ± 22.4	85.6 ± 49.5	219.7 ± 322.7
Chen et al 2020	Retrospective	China	COVID-19	99	7.5 ± 3.6	0.9 ± 0.5	51.4 ± 41.8	39 ± 7.8	34 ± 5.5	75.6 ± 25	85 ± 33.3
Xu et al 2020	Retrospective	China	COVID-19	62	4.7 ± 1.7	1.0 ± 0.5	NA	22 ± 14.8	26 ± 8.9	72.0 ± 17	69.0 ± 44.8
Zhang et al 2020	Retrospective	China	COVID-19	140	4.7 ± 0.8	0.8 ± 0.1	34.2 ± 13.7	NA	NA	NA	72.5 ± 15.7
Li et al 2020	Retrospective	China	COVID-19	425	NA	NA	NA	NA	NA	NA	NA
Alfaraj et al 2020	Retrospective	Saudi Arabia	MERS-COV	314	NA	NA	NA	NA	NA	NA	NA
Arabi et al 2019	Retrospective	Saudi Arabia	MERS-COV	144	NA	NA	NA	NA	NA	114.9 ± 177.8	NA
Ahmadzadeh et al 2019	Retrospective	Iran	MERS-COV	107	NA	NA	NA	NA	NA	NA	NA
Habib et al 2019	Retrospective	Saudi Arabia	MERS-COV	63	NA	NA	NA	NA	NA	NA	NA
Al-Baadani et al 2018	Retrospective	Saudi Arabia	MERS-COV	82	NA	NA	NA	NA	NA	NA	NA
Hwang et al 2018	Retrospective	Janpan	MERS-COV	7	5.9 ± 2.8	NA	2.6 ± 4.1	25.4 ± 5.3	32.9 ± 5.6	NA	181.3 ± 195
Ahmed et al 2018	Retrospective	Saudi Arabia	MERS-COV	883	NA	NA	NA	NA	NA	NA	NA
Garout et al 2018	Retrospective	Saudi Arabia	MERS-COV	52	NA	NA	NA	NA	NA	NA	NA
Shalhoub et al 2018	Retrospective	Saudi Arabia	MERS-COV	32	NA	NA	NA	49.6	NA	69	NA
Kim et al 2017	Retrospective	South Korea	MERS-COV	186	NA	NA	NA	NA	NA	NA	NA
Kang et al 2017	Retrospective	South Korea	MERS-COV	171	NA	NA	NA	NA	NA	NA	NA

NA

NA

NA

NA

NA

NA

NA

 0.48 ± 0.2

 0.9 ± 0.4

 0.9 ± 0.6

NA

NA

NA

NA

NA

25.2 ± 169.7

NA

NA

NA

NA

NA

NA

NA

NA

 27 ± 272.3

NA

 29 ± 72

NA

NA

 60.5 ± 1820

 29 ± 22.4

49 ± 37.8

 41 ± 27.5

ALT: Alamine aminotransferase,

NA

NA

 53 ± 184.8

NA

39 ± 95

NA

NA

92.5 ± 1041

59 ± 43

 72 ± 52.3

59.6 ± 59.5

NA

170.1 ± 222.4

 90 ± 240.8

NA

 80 ± 374.8

NA

NA

84 ± 55.8

 106.5 ± 95.9

 162 ± 269.3

 3.3 ± 2.5

AST: Aspartate aminotransferase, SD: Standard Deviation

NA

104.5 ± 253.2

NA

NA

NA

NA

NA

123.5 ± 1502

NA

NA

NA

NA

 7.5 ± 3.9

 9.1 ± 3.6

NA

 4.3 ± 7.4

NA

NA

 4.3 ± 4.9

 7.4 ± 4.1

 8.9 ± 4.9

 13.3 ± 10.9

MERS-COV: Middle East Respiratory Syndrome-Coronavirus, WBC: White Blood Cell, CRP: C-Reactive Protein,

MERS-COV

23

25

14

39

186

255

30

8

70

12

Table3. Quality Assessment of Included Studies

Study	Selection	Comparability	Outcome	Total scores
Backer et al 2020	4	1	2	7
Chan et al 2020	4	2	2	8
Song et al 2020	4	2	2	8
Huang et al 2020	4	2	2	8
Wang et al 2020	4	2	2	8
Liu et al 2020	4	1	2	7
Li et al 2020	3	2	2	7
Chen et al 2020	4	1	2	7
Xu et al 2020	4	1	2	7
Zhang et al 2020	4	1	2	7
Alfaraj et al 2020	4	2	2	8
Arabi et al 2019	4	2	2	8
Ahmadzadeh et al 2019	4	2	2	8
Habib et al 2019	4	1	2	7
Al-Baadani et al 2018	4	2	2	8
Hwang et al 2018	4	2	2	8
Ahmed et al 2018	4	2	2	8
Garout et al 2018	4	2	2	8
Shalhoub et al 2018	4	1	2	7
Kim et al 2017	4	1	2	7
Kang et al 2017	4	2	2	8
Kim et al 2017	3	1	2	6
Garbati et al 2016	4	1	2	7
Khalid et al 2016	4	1	2	7
Alraddadi et al 2016	4	1	2	7
Choi et al 2016	4	1	2	7
Al-Hameed et al 2015	3	1	2	6
Oboho et al 2015	3	1	2	6
Cha et al 2015	4	1	2	7
Saad et al 2014	4	1	2	7
Arabi et al 2014	4	1	2	7
Al-Tawfiq et al 2013	3	1	2	6

Table 4. Description of Clinical Symptoms in COVID-19 and MERS-COV Populations

Symptom

Fever	480 (45.2%)	404 (14.9%)
Cough	373 (35.1%)	424 (15.7%)
Generalised weakness and myalgia	318 (29.9%)	337 (12.4%)
Stuffy and Rhinorrhoea	6 (0.6%)	17 (0.6%)
Pharyngalgia	32 (3%)	47 (1.7%)
Chest pain	10 (0.9%)	27 (1%)
Diarrhoea or Anorexia	123 (11.6%)	128 (4.7%)
Dyspnoea	140 (13.2%)	271 (10%)
Dizziness or headache	60 (5.6%)	131 (4.8%)

COVID-19: Corona Virus Disease-19, MERS-COV: Middle East Respiratory Syndrome-Coronavirus Disease

COVID-19, No (n/total %)

MERS-COV, No (n/total %)

Table 5. Distribution of Complications in COVID-19 and MERS-COV Populations

Complication

Shook

Neurological symptoms

ARDS: Acute Respiratory Distress Syndrome

Snock	17 (1.0%)	22 (0.8%)
Arrhythmia	28 (2.6%)	11 (0.4%)
ARDS	51 (4.8%)	83 (3.1%)
Acute cardiac injury	11 (1%)	10 (0.4%)
Acute kidney injury	10 (0.9%)	30 (1.1%)
Acute liver injury	2 (0.2%)	22 (0.8%)

COVID-19: Corona Virus Disease-19, MERS-COV: Middle East Respiratory Syndrome-Coronavirus Disease

COVID-19, No (n/total %)

17 (1 60/)

0

MERS-COV, No (n/total %)

22 (0 80/1)

4 (0.1%)

Table 6. Distribution of Comorbidities in COVID-19 and MERS-COV Populations

Comorbidity	COVID-19, No (n/total %)	MERS-COV, No (n/total %)
Diabetes	43 (4%)	247 (9.1%)
Hypertension	101 (9.5%)	244 (9%)
Cardiovascular disease	77 (7.3%)	161 (5.9%)
Chronic obstructive pulmonary disease	10 (0.9%)	83 (3.1%)
Malignancy	19 (1.8%)	70 (2.6%)
Chronic liver disease	24 (2.3%)	28 (1%)
Cerebrovascular disease	13 (1.2%)	47 (1.7%)
Chronic kidney disease	5 (0.5%)	167 (6.2%)
Obesity	0	42 (1.6%)

COVID-19: Corona Virus Disease-19, MERS-COV: Middle East Respiratory Syndrome-Coronavirus

Table 7. Clinical and Laboratory Characteristics of COVID-19 versus MERS-COV

Standard Eorror of Mean, *: Significant Difference

Characteristics	Mean ± SEM	MERS-COV Mean ± SEM	P value			
Age (y)	50.9 ± 2	53.6 ± 1.5	0.3			
Incubtion time (d)*	5.1 ± 0.5	7.4 ± 0.4	0.02			
WBC (x 10 ⁹ cells/L)	5.7 ± 0.4	7.6 ± 1	0.1			
Lymphocyte count (x 109 cells/L)	1.1 ± 0.1	0.8 ± 0.1	0.2			
CRP (mg/L)	37.6 ± 5.8	13.9 ± 11.3	0.1			
ALT (U/L)	28 ± 3.1	37.3 ± 5.1	0.2			
AST (U/L)*	31.5 ± 2.4	58.3 ± 7.6	0.009			
Creatinine (umol/L)	74.5 ± 2.5	101.4 ± 18.5	0.2			
Creatine kinase (U/L)	109.1 ± 20	136.4 ± 23.1	0.5			
COVID-19: Corona Virus Disease-19, MERS-COV: Middle East Respiratory Syndrome-Coronavirus, WBC: White Blood Cell, CRP: C-Reactive Protein, ALT: Alamine aminotransferase, AST: Aspartate aminotransferase, SEM:						

COVID-19

MERS-COV

RECORDS IDENTIFIED

THROUGH DATABASE

RECORDS EXCLUDED AFTER TITLE

AND ABSTRACT SCREENING WITH







